Adrenergic beta-antagonist: Difference between revisions
Jump to navigation
Jump to search
imported>Robert Badgett No edit summary |
imported>Robert Badgett mNo edit summary |
||
| Line 2: | Line 2: | ||
'''Adrenergic beta-receptor blockaders''' ('''beta-blockers''') are "drugs that bind to but do not activate beta-adrenergic receptors thereby blocking the actions of beta-adrenergic agonists. Adrenergic beta-antagonists are used for treatment of [[hypertension]], cardiac arrhythmias, angina pectoris, glaucoma, [[migraine]] headaches, and anxiety".<ref>{{MeSH}}</ref> | '''Adrenergic beta-receptor blockaders''' ('''beta-blockers''') are "drugs that bind to but do not activate beta-adrenergic receptors thereby blocking the actions of beta-adrenergic agonists. Adrenergic beta-antagonists are used for treatment of [[hypertension]], cardiac arrhythmias, angina pectoris, glaucoma, [[migraine]] headaches, and anxiety".<ref>{{MeSH}}</ref> | ||
Beta-blockers vary within the class regarding intrinsic sympathomimetic activity (ISA), [[Adrenergic receptor|beta 1-selectivity]], membrane stabilizing activity, lipophilicity, and metabolism. This may lead to different effectiveness among this class of drugs. A meta-analysis has concluded that metoprolol may be the best beta-blocker for secondary prevention of [[myocardial infarction]].<ref name="pmid9122425">{{cite journal |author=Soriano JB, Hoes AW, Meems L, Grobbee DE |title=Increased survival with beta-blockers: importance of ancillary properties |journal=Prog Cardiovasc Dis |volume=39 |issue=5 |pages=445–56 |year=1997 |pmid=9122425 |doi= |url=http://linkinghub.elsevier.com/retrieve/pii/S0033-0620(97)80039-4 |issn=}}</ref> | Beta-blockers vary within the class regarding intrinsic sympathomimetic activity (ISA), [[Adrenergic receptor|beta 1-selectivity]], membrane stabilizing activity, lipophilicity, and metabolism. This may lead to different effectiveness among this class of drugs. A [[meta-analysis]] has concluded that [[metoprolol]] may be the best beta-blocker for [[secondary prevention]] of [[myocardial infarction]].<ref name="pmid9122425">{{cite journal |author=Soriano JB, Hoes AW, Meems L, Grobbee DE |title=Increased survival with beta-blockers: importance of ancillary properties |journal=Prog Cardiovasc Dis |volume=39 |issue=5 |pages=445–56 |year=1997 |pmid=9122425 |doi= |url=http://linkinghub.elsevier.com/retrieve/pii/S0033-0620(97)80039-4 |issn=}}</ref> | ||
==References== | ==References== | ||
<references/> | <references/> | ||
Revision as of 10:14, 19 May 2008
Adrenergic beta-receptor blockaders (beta-blockers) are "drugs that bind to but do not activate beta-adrenergic receptors thereby blocking the actions of beta-adrenergic agonists. Adrenergic beta-antagonists are used for treatment of hypertension, cardiac arrhythmias, angina pectoris, glaucoma, migraine headaches, and anxiety".[1]
Beta-blockers vary within the class regarding intrinsic sympathomimetic activity (ISA), beta 1-selectivity, membrane stabilizing activity, lipophilicity, and metabolism. This may lead to different effectiveness among this class of drugs. A meta-analysis has concluded that metoprolol may be the best beta-blocker for secondary prevention of myocardial infarction.[2]
References
- ↑ Anonymous (2024), Adrenergic beta-antagonist (English). Medical Subject Headings. U.S. National Library of Medicine.
- ↑ Soriano JB, Hoes AW, Meems L, Grobbee DE (1997). "Increased survival with beta-blockers: importance of ancillary properties". Prog Cardiovasc Dis 39 (5): 445–56. PMID 9122425. [e]